Floatz logo

LEVODOPA

Chronic Low-back Pain

Northwestern UniversitySmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

19 Active assets in the Chronic Low-back Pain cohort.

Asset / SponsorPhaseRating
NEPENTHE
Uskudar University
Phase 4BB
Duloxetine
University of North Carolina, Chapel Hill
Phase 4BB
Dfn-15
Laboratorios Silanes S.A. de C.V.
Phase 3B
carbidopa
Northwestern University
Phase 2CCC
Naproxen
Northwestern University
Phase 2CCC

View all 20 →

Same molecule, other indications

LEVODOPA is also rated in:

drug-induced dyskinesiaDormant
A
Indicative ·
80 / 100
View asset →
Parkinson diseaseDormant
BBB
Indicative ·
75 / 100
View asset →
movement disorderDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →